(-) AstraZeneca halts development of anti-obesity drug (Market Watch) - Sep 7, 2012 - AstraZeneca decided to discontinue further development of an obesity drug, AZD2820 after a clinical trial for the treatment was halted as a man enrolled in the study became ill
Discontinued • Obesity
|
|
Palatin Technologies Inc. PTN -0.45% said its collaboration partner AstraZeneca PLC (AZN, AZN.LN) has decided to discontinue further development of an obesity drug after a clinical trial for the treatment was halted as a man enrolled in the study became ill.
AstraZeneca's safety review committee in June halted the Phase 1 trial of AZD2820 after a serious adverse event was reported. The affected subject, who may have suffered an allergic reaction after his first dose, was treated at the site and fully recovered.
...
The company also said the investigation determined that it is unlikely that the serious adverse event was related to melanocortin receptor activation as an approach for the treatment of obesity.
IR 8
|